Verona Pharma plc — Director's Dealing 2024

Sep 13, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2024-09-11

Reporting Person: ZACCARDELLI DAVID (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-11	Ordinary Shares	S	600000	$3.7572	Disposed	15250704	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 8, 2024.

F3: The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $3.75 to $3.7888 per Ordinary Share, inclusive (or $30.00 to $30.31 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F4: Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 12,425,704 Ordinary Shares underlying 1,553,213 ADSs.